VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 1: Epidemiology, Pathophysiology, and Clinical Presentations.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 42607951.
- Also identified by DOI 10.1016/j.jaad.2026.08.041.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a newly recognized, ubiquitin-activating enzyme E1 (UBA1)-mediated autoinflammatory disorder characterized by treatment-refractory systemic inflammation and diverse cutaneous findings. Dermatologists are uniquely positioned to facilitate early diagnosis because skin involvement occurs frequently and often precedes multi-organ disease. This 2-part continuing medical education series provides an up-to-date overview of VEXAS syndrome. Part 1 reviews epidemiology, pathogenesis, and key clinical and laboratory features, emphasizing dermatologic presentations that should raise suspicion for VEXAS syndrome. Part 2 outlines the diagnostic work-up, including bone marrow findings, definitive UBA1 genetic testing, and management strategies alongside emerging data on prognosis. Together, these articles equip clinicians to recognize VEXAS syndrome, differentiate it from common mimickers, and guide appropriate evaluation and treatment.